Is Lusutrombopag approved by the US FDA?

Drugs@FDA lists 1 application product line for Lusutrombopag, including MULPLETA (Prescription).

Is Lusutrombopag authorised in the European Union?

EMA lists 0 centrally authorised medicines containing Lusutrombopag.

Active substance

Lusutrombopag

US FDA 1
EMA 1

US FDA United States — FDA approvals (Drugs@FDA)

Product	Strength	Form · route	Applicant	Status	First approved
MULPLETA	3MG	tablet · oral	VANCOCIN ITALIA	Prescription	31 Jul 2018

EMA European Union — centrally authorised medicines

Mulpleo (previously Lusutrombopag Shionogi) Shionogi B.V. · Withdrawn · authorised 18 Feb 2019 · ATC B02BX

Therapeutic indication (EMA)

Mulpleo is indicated for the treatment of severe thrombocytopenia in adult patients with chronic liver disease undergoing invasive procedures

Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.